Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Financial Results (Aug 5, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 5, 2026
Period End
August 5, 2026
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Jan ’22Jan ’22
  4. Leadership change8-K · Sep ’25Sep ’25

Summary

Summary of the 8-K filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported second-quarter 2026 results for the quarter ended June 27, 2026, with revenue of $1.00 billiona, down 2.7% from $1.03 billion a year earlier, and organic revenue growth of 0.1%.

GAAP results were weaker, with a net loss attributable to common shareholders of $(1.5) million, or $(0.03) per diluted share, compared with net income of $52.3 millionb, or $1.06 per share, a year earlier. The company attributed the decline mainly to a $63.7 million, or $1.40 per share, loss on the CDMO and Cell Solutions divestiture. On a non-GAAP basis, diluted EPS was $3.02, versus $3.12 in the prior-year quarter, and the non-GAAP operating margin fell to 20.5% from 22.1%, mainly on higher study-related direct costs in the DSA segment.

Management cited improving demand, particularly in the DSA segment, where it recorded the highest net book-to-bill in nearly four years. Based on second-quarter performance and improving demand trends, the company raised its 2026 guidance: organic revenue growth is now 0.0% to 1.0% (previously (1.5)% to (0.5)%), and non-GAAP EPS is now $11.15 to $11.45c (previously $10.80 to $11.30). GAAP EPS guidance was lowered to $3.05 to $3.35 from $5.35 to $5.85, primarily because of the divestiture-related net loss.

The company also repurchased $100.0 milliond of stock in the quarter and has $700.0 million remaining under its $1.0 billion authorization. An Investor Day is scheduled for September 24, 2026.

Key Highlights

  1. Q2 2026 revenue was $1.00 billion, down 2.7% year over year, with organic revenue growth of 0.1%, the highest level since the third quarter of 2023.
  2. GAAP net loss attributable to common shareholders was $(1.5) million, or $(0.03) per diluted share, driven mainly by a $63.7 million ($1.40 per share) loss on the CDMO and Cell Solutions divestiture.
  3. Non-GAAP diluted EPS was $3.02, down from $3.12, and the non-GAAP operating margin was 20.5% versus 22.1%, reflecting higher study-related direct costs in DSA.
  4. 2026 non-GAAP EPS guidance was raised to $11.15–$11.45 from $10.80–$11.30, and organic revenue growth guidance was raised to 0.0%–1.0% from (1.5)%–(0.5)%.
  5. 2026 GAAP EPS guidance was reduced to $3.05–$3.35 from $5.35–$5.85, primarily due to the net loss on divestitures.
  6. DSA segment revenue was $606.5 million with 0.2% organic growth, and the company reported its highest net book-to-bill in nearly four years.
  7. The company repurchased $100.0 million of common stock in Q2 at an average price of $174 per share, leaving $700.0 million under its $1.0 billion authorization.

Frequently Asked Questions

  1. Why did GAAP results decline so sharply while non-GAAP results were closer to prior-year levels?

    The GAAP net loss of $(1.5) million, or $(0.03) per diluted share, compared with net income of $52.3 million, or $1.06 per share, in Q2 2025 was principally due to a $63.7 million ($1.40 per share) loss on the CDMO and Cell Solutions divestiture. Non-GAAP diluted EPS excludes this and other items, and came in at $3.02 versus $3.12 a year earlier.

  2. What changed in the 2026 guidance?

    Non-GAAP EPS guidance was raised to $11.15–$11.45 from $10.80–$11.30, and organic revenue growth guidance was raised to 0.0%–1.0% from (1.5)%–(0.5)%. The company cited operational outperformance, including in Q2, driven by improving DSA demand and better-than-expected Manufacturing performance. GAAP EPS guidance was lowered to $3.05–$3.35 from $5.35–$5.85.

  3. Why did margins decline in the DSA segment?

    The non-GAAP operating margin for DSA decreased to 25.6% from 27.4%, primarily because of higher study-related direct costs. Its GAAP operating margin rose to 20.5% from 19.9%, helped by lower amortization of intangibles related to the European Discovery Services divestiture and lower third-party legal costs related to an NHP supply matter.

  4. What is the company doing with its capital?

    In Q2 2026, Charles River repurchased 0.6 million shares for $100.0 million, at an average price of $174 per share. Year to date it repurchased 1.7 million shares for $300.0 million. As of June 27, 2026, $700.0 million remained under the $1.0 billion authorization approved by the Board on October 29, 2025.

  5. What upcoming events should investors watch?

    Charles River will host an Investor Day on Thursday, September 24, 2026, at 9:00 a.m. ET, webcast live on its Investor Relations website. The company also completed the divestitures of certain European Discovery Services sites and its CDMO and Cell Solutions businesses in May 2026.